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Abstract: Diabetes mellitus is part of the insulin resistance syndrome, which includes 
  hypertension, dyslipidemia, and obesity as its other components. Conversely, insulin   resistance 
is a major pathophysiologic factor in the development of type 2 diabetes. It makes sense, 
therefore, to choose an anti-diabetic medication that acts on insulin resistance and its clini-
cal components, while having anti-hyperglycemic effects as well. This review discusses the 
non-glycemic, or extra-pancreatic effects, including insulin sensitization, of liraglutide, a 
novel GLP-1 analog.
Keywords: liraglutide, GLP-1 analog, weight modulation, systolic blood pressure, cardiopro-
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Introduction
Diabetes mellitus is part of the insulin resistance syndrome (IRS), which includes 
hypertension, dyslipidemia, and obesity as its other components. In the initial 
stages insulin resistance is compensated by increased insulin secretion. However 
the disease is progressive, with continuous b-cell failure leading to inadequately 
increased insulin secretion in relation to the degree of insulin resistance. Present 
data show that in insulin resistance, the incretin hormone (GIP and GLP-1) responses 
to a mixed meal are impaired and are related to the degree of insulin resistance.1 
In this regard therapeutic use of GLP-1 analogs offers a novel approach to address 
insulin resistance.
Liraglutide is a GLP-1 analog with 97% homology to the amino acid sequence 
of human GLP-1.2 The attachment of C16 fatty acid chain helps delay absorption of 
liraglutide by forming a heptamer, and delays degradation by DPP-4.3 Liraglutide 
is thus able to effectively mimic the actions of mature GLP-1, and improve insulin 
secretion as well as response.
Glycemic effects
Liraglutide reduces plasma glucose levels in both fasting and post prandial state, thus 
achieving improvement in hemoglobin A1c (HbA1c).4 It does so by increasing insulin 
secretion, reducing post-prandial glucagon secretion, delaying gastric emptying, 
improving b-cell function, and reducing appetite.5
The glucoregulatory effects, and results of clinical trials with respect to glycemic 
control, are discussed in detail in other reviews.5Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Extra-glycemic/pleiotropic effects
Liraglutide has been shown to have beneficial effects on other 
components of the IRS, such as body weight, blood pressure 
and lipids. This article reviews the recent data from animal 
and clinical studies.
Energy intake
In animal studies, liraglutide has been shown to be   associated 
with a reduction in dietary calorie intake and a change in 
food preference. In one study, female rats made obese by 
candy-feeding were randomized to 0.2 mg/kg liraglutide 
twice daily, 10 mg/kg vildagliptin twice daily, vehicle only 
or chow-only diet. The rats were subjected to oral glucose 
tolerance tests, energy expenditure measurement, and body 
composition analysis by dual-energy x-ray absorptiometry, 
as well as histology to assess pancreatic- b-cell mass. Control 
animals developed weight gain as well as fat gain.
Liraglutide administration fully reversed the weight and 
fat gains noted with candy-feeding, decreased calorie intake, 
and shifted food preference from candy to chow. Liraglutide 
did not reduce energy expenditure in spite of weight loss, 
thus highlighting another dimension of its mechanism of 
action.6
Liraglutide may have the ability to change food prefer-
ences, and thus reduce energy intake in human beings as 
well, as evidenced by anecdotal reports. Similar results have 
been seen in clinical studies. Liraglutide given as a 1.8 mg 
daily dose reduced hunger in two studies. A similar dose 
was noted to reduce energy intake in one of these studies. 
However, a lower dose (0.6 mg %) was not associated with 
such effects.7–9
Body weight
Liraglutide 1.2 mg and 1.8 mg have been found to reduce 
body weight in most studies. In the LEAD-3 trial, which 
compared subcutaneous liraglutide once daily with oral 
glimepiride 8 mg once daily for 52 weeks in 746 subjects 
of type 2 diabetes, body weight fell by 2 kg and 2.5 kg 
respectively in the 1.2 mg and 1.8 mg liraglutide group, but 
increased by 1.1 kg in the glimepiride group (P , 0.0001 
for both liraglutide groups vs glimepiride).10
The weight loss was maximal during first 16 weeks of 
therapy, and was not related to nausea. Weight remained 
stable over one year, after the initial improvement.
Another study was done over 24 weeks to compare a 
lower dose of liraglutide (0.9 mg once daily) (n = 268) and 
glibenclamide (n = 132) in Japanese patients. It found a 
weight loss of 1.91 kg in the liraglutide group as compared 
to glibenclamide group (P , 0.0001) in spite of the lower 
dose used, and better glycemic control.11
Similar results have been noted in studies using liraglutide 
as combination therapy. In studies LEAD-2 (n = 1087), 
LEAD-4 (n = 533) and LEAD-5 (n = 581), liraglutide led to 
significant reductions in weight, across the full spectrum of 
baseline body mass index.12–14 Maximal weight loss was noted 
in patients with a higher baseline BMI ($35 kg m-2).15
In the LEAD-1 study, which compared addition of vari-
ous doses of liraglutide with rosiglitazone and placebo to 
baseline glimepiride therapy, weight change seen with lira-
glutide 1.2 mg and 1.8 mg was significantly different from 
rosiglitazone (1.8 kg difference for the 1.2 mg group and 
2.3 kg for the 1.8 mg group). However, the difference was 
not significant when compared with the placebo group.16
In the LEAD-2 trial, which compared addition of lira-
glutide to glimepiride or placebo on a base of metformin, 
liraglutide 0.6 mg showed a 2.8 kg difference, liraglutide 
1.2 mg had a 3.6 kg difference and liraglutide 1.8 mg had 
3.8 kg difference with respect to glimepiride. All these dif-
ferences were significant (P # 0.01).12
The LEAD-4 trial compared liraglutide 1.2 mg and 
1.8 mg with placebo, when added to a metformin and rosigli-
tazone combination. The difference in weight with respect 
to placebo, was 1.6 kg and 2.6 kg for the 1.2 mg and 1.8 mg 
liraglutide groups (P , 0.0001).13
A similar level of statistical significance was noted for 
liraglutide 1.8 mg, versus insulin (difference in weight change 
3.43 kg) in the LEAD-5 trial, where the baseline therapy was 
metformin and glimepiride.14
Weight gain or excessive body weight is also associated 
with public distress. The LEAD-2 reported this domain in 
the Impact of Weight on Quality of Life questionnaire, and 
found less distress due to body weight with liraglutide than 
with glimepiride (P , 0.02).17
The weight loss that occurs with liraglutide is predomi-
nantly of visceral fat.18 Available preclinical and clinical 
data clearly demonstrate the utility of liraglutide in reducing 
weight, thus making it a drug of choice for obese patients 
with diabetes. Weight loss has been demonstrated to 
improve therapeutic outcomes and reduce complications 
in overweight diabetics. The correction of this important 
part of insulin resistance syndrome, should, in principle, 
lead to improved cardiovascular outcomes. This should in 
turn encourage the use of liraglutide as a drug of choice 
for diabetes.
Studies are also planned to assess the effect of liraglutide 
in obese, but non-diabetic individuals.Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Blood pressure
Hypertension is another component of insulin resistance, 
and frequent comorbid condition of diabetes, which need 
to be addressed.
Systolic blood pressure reduced by 3.6 mmHg with 
liraglutide 1.8 mg (P , 0.0118 versus glimepiride), and by 
2.1 mmHg with liraglutide 1.2 mg (P = NS vs glimepiride) 
in the LEAD-3 trial. Non-significant decreases in diastolic 
blood pressure were reported in the same study.19
These results have led to the realization that liraglutide 
is effective not only in correcting hyperglycemia but also 
has pleiotropic effects such as blood pressure lowering. 
Similar results have been reported from other LEAD tri-
als, where liraglutide has been studied in combination with 
other drugs.
Liraglutide 1.8 mg has demonstrated lowering of systolic 
blood pressure by 1.4–4.5 mmHg in LEAD-1, -2 and -5, 
reaching statistical significance in the latter (P , 0.05). The 
reduction noted with liraglutide was significant when com-
pared with the reduction of systolic blood pressure seen with 
placebo in LEAD-4.12–14 No significant change in diastolic 
blood pressure has been noted.
Insulin resistance
Measures of insulin resistance, ie, homeostasis model assess-
ment of insulin resistance (HOMA-IR), have been studied 
in LEAD trials.
In LEAD-3, the monotherapy trial, insulin resistance 
decreased by 0.65% with liraglutide 1.2 mg (P = 0.0249 vs 
glimepiride) and 1.35% with liraglutide 1.8 mg (P = 0.0011 
vs glimepiride), while increasing by 0.85% in the glimepiride 
group. No significant differences were reported between 
groups of indices of b-cell function.20
LEAD-1 and -2, however, did not report any improve-
ment in insulin sensitivity with liraglutide.20
Cardiovascular markers
Liraglutide has been shown to reduce triglyceride levels, 
without affecting concentration of other lipids.21 This makes 
it an attractive choice for patients with diabetic dyslipidemia, 
which is characterized by high levels of triglycerides.
While no long term data of cardiovascular outcomes is 
available, other studies show a cardio protective effect of lira-
glutide. The drug reduces levels of B-type natriuretic peptide 
and plasminogen activator inhibitor-1 (PAI-1) in humans.22 
Similar effects on PAI-1 and ICAM-1 have been demonstrated 
in vitro. Healthy volunteers given liraglutide have shown no 
effect on cardiac repolarization (corrected QT interval).23
Tolerability
Liraglutide is generally well tolerated. The most common 
adverse events are gastrointestinal, ie, nausea, vomiting, and 
diarrhea, and decrease over time. Hypoglycemia occurs rarely, 
and no major hypoglycemic events have been reported with 
liraglutide monotherapy (LEAD-3), liraglutide +   metformin 
(LEAD-2), and liraglutide + metformin +   rosiglitazone 
(LEAD-4).20
In LEAD-3, the incidence of minor hypoglycemia was 
0.30 and 0.25 events/patient/year with liraglutide 1.2 mg and 
1.8 mg/day, as compared to 1.96 events with glimepiride 
(both P , 0.0001). After 2 years, the rates were 0.16 and 
0.28 for the liraglutide group, and 1.82 events/patient/year for 
glimepiride (P , 0.0001 and P , 0.0001 respectively).
As liraglutide appears to be safe, well-tolerated, and 
associated with a negligible incidence of hypoglycemia, it 
may find a place in the management of insulin resistance 
syndrome.
Conclusion
Liraglutide is a GLP-1 analogue with proven efficacy, safety, 
and tolerability as a glucose lowering drug, when used in type 2 
diabetes mellitus. A detailed analysis of its pleiotropic or extra 
glycemic effects, however, reveals a multifaceted character of 
the molecule. Liraglutide is effective in reducing body weight, 
decreasing visceral fat, lowering systolic blood pressure, and 
improving lipid profile as well as other   cardiovascular risks 
markers, while reducing insulin resistance.
These beneficial effects on all components of the insulin 
resistance syndrome, or metabolic syndrome, with minimal 
risk of hypoglycemia, make liraglutide an attractive option 
for management of insulin resistance.
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